FDA accepted the BLA resubmission for RP1 in advanced melanoma, with a decision expected by August 2026. Cash reserves declined to $268.9 million, funding operations into early 2027. RP1 and RP2 clinical programs showed strong survival and response rates in recent trials.Original document: Replimun…
FDA accepted the BLA resubmission for RP1 in advanced melanoma, with a decision expected by August 2026. Cash reserves declined to $268.9 million, funding operations into early 2027. RP1 and RP2 clinical programs showed strong survival and response rates in recent trials.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
